Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today reported a substantial reduction in tumor burden from a single-patient expanded access case in ...

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Celcuity Inc. is one of them. Celcuity Inc. (NASDAQ:CELC) is a clinical-stage biotechnology company developing ...

Penn Medicine researchers found two oral drugs eliminated dormant breast cancer cells in most patients, with relapse rates ...

Advanced ER-positive breast cancer patients on giredestrant and Afinitor had better progression-free survival versus standard therapy in the evERA trial.

Animal studies say rapamycin can slow aging – but does it work in humans? A new review finds the evidence for the off-label, ...

The firm, which so far has focused on cancer, expects to file an IND application for a treatment for tyrosinemia type I and alkaptonuria next year.

Kazia Therapeutics ( ($KZIA) ) just unveiled an announcement. On September 11, 2025, Kazia Therapeutics announced significant findings from a ...

The emergence of drug resistance remains one of the greatest challenges in effective cancer therapy. Despite advances in ...

Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus ...